West Pharmaceutical Services (NYSE:WST) Announces Quarterly Earnings Results

West Pharmaceutical Services (NYSE:WST) released its quarterly earnings data on Thursday. The medical instruments supplier reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.07, Zacks reports. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The business had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million. West Pharmaceutical Services updated its FY 2025 guidance to 6.000-6.200 EPS.

West Pharmaceutical Services Stock Up 7.9 %

Shares of West Pharmaceutical Services stock traded up $15.73 on Friday, reaching $214.84. The company’s stock had a trading volume of 5,020,477 shares, compared to its average volume of 424,824. The company has a market capitalization of $15.56 billion, a price-to-earnings ratio of 31.87, a P/E/G ratio of 19.31 and a beta of 1.01. The firm’s fifty day simple moving average is $327.86 and its two-hundred day simple moving average is $313.82. West Pharmaceutical Services has a 52 week low of $197.01 and a 52 week high of $400.88. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend was Friday, February 7th. West Pharmaceutical Services’s payout ratio is 12.46%.

Wall Street Analysts Forecast Growth

WST has been the subject of several research analyst reports. Bank of America increased their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Wolfe Research initiated coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. KeyCorp lowered their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research note on Friday. StockNews.com upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $350.00 to $390.00 in a research note on Thursday, December 12th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $344.00.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.